Joachim Drevs | Academic Influence

Joachim Drevs's AcademicInfluence.com Rankings

Joachim Drevs

Computer Science

#12581

World Rank

#13462

Historical Rank

Machine Learning

#5802

World Rank

#5885

Historical Rank

Artificial Intelligence

#6252

World Rank

#6356

Historical Rank

Database

#9695

World Rank

#10251

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Joachim Drevs's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Joachim Drevs Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Joachim Drevs is a German medical specialist in internal medicine with a focus on hematology and oncology, as well as a university professor at the University Medical Center Freiburg and former leader of the Health Center at the University Clinic in Tübingen.

(See a Problem?)

Joachim Drevs's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. (2000) (862)
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. (2000) (320)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. (2007) (299)
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. (2002) (246)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours (2003) (213)
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. (2002) (211)
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. (2003) (181)
First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. (2014) (177)
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. (2005) (168)
A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. (2000) (146)
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. (2005) (129)
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. (2012) (127)
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study (2004) (121)
PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration (2000) (107)
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. (2003) (101)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. (2003) (98)
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. (2004) (97)
Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin (2007) (89)
Receptor tyrosine kinases: the main targets for new anticancer therapy. (2003) (80)
Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. (2003) (79)
Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. (2001) (76)
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. (2009) (72)
Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors (2005) (67)
Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy (2011) (66)
VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity (2008) (62)
Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study (2007) (50)
The use of vascular biomarkers and imaging studies in the early clinical development of anti‐tumour agents targeting angiogenesis (2006) (48)
Liver cancer: Targeted future options. (2011) (43)
Implications of Vascular Endothelial Growth Factor, sFlt-1, and sTie-2 in Plasma, Serum and Cerebrospinal Fluid during Cerebral Ischemia in Man (2003) (41)
Antiangiogenesis: Current Clinical Data and Future Perspectives (2002) (41)
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma (2005) (40)
Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. (2008) (39)
Development of Albumin‐binding Doxorubicin Prodrugs that are Cleaved by Prostate‐specific Antigen (2005) (38)
Receptor tyrosine kinases and anticancer therapy. (2005) (37)
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584 (2003) (35)
PTK 787 / ZK 222584 , a Specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor , Affects the Anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as Detected by Dynamic Enhanced Magnetic Resonance Imaging 1 (2002) (35)
Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice (2005) (33)
Mode of action and clinical impact of VEGF signaling inhibitors (2009) (29)
VEGF and angiogenesis: implications for breast cancer therapy (2008) (25)
Molecular Targeted Therapies for Solid Tumors: Management of Side Effects (2009) (25)
Plasma vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE-2 in patients with dural arteriovenous fistulas: a pilot study (2005) (24)
Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine (2004) (23)
Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. (2009) (22)
DCE-MRI in clinical trials: data acquisition techniques and analysis methods. (2003) (20)
Soluble markers for the detection of hypoxia under antiangiogenic treatment. (2003) (20)
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. (2009) (19)
Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases. (2004) (19)
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours (2012) (18)
In Vivo and In Vitro Efficacy of an Acid-Sensitive Albumin Conjugate of Adriamycin Compared to the Parent Compound in Murine Renal-Cell Carcinoma (1999) (17)
Effects of PTK 787 / ZK 222584 , a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , on Primary Tumor , Metastasis , Vessel Density , and Blood Flow in a Murine Renal Cell Carcinoma Model 1 (2000) (17)
Angiogenesis and the ET-1/ETA Receptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors (2004) (14)
Soluble Tie‐2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma (2002) (13)
Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studies (2007) (11)
Angiogenesis Inhibition: Drugs in Clinical Trials (1999) (10)
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. (2010) (8)
Phase I dose escalating study of PEG-PGA and DON (GlutaDON): A new amino acid depleting anti cancer drug approach. (2004) (8)
The role of bisphosphonates in oncology (2004) (7)
PTK/ZK (Novartis). (2003) (7)
First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors. (2011) (7)
A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors (2008) (6)
Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma--what is a useful tool in clinical studies of anti-angiogenic drugs? (2002) (6)
Phase I dose-escalation and pharmacokinetic (PK) study of a(6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers (2004) (5)
Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK) (1999) (5)
AMT: preclinical pharmacology studies. (2009) (4)
Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging (2016) (4)
Antimetastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumors. (2012) (4)
Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma (2004) (4)
Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model. (2011) (4)
Surrogate marker in clinical studies with anti-angiogenic drugs. (2003) (4)
A pilot study of Auron Misheil Therapy in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life data. (2009) (4)
Relationship to retinopathy of prematurity (2008) (4)
Phase I dose-escalation and pharmacokinetic (PK) study of a(6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers. (2005) (3)
Bisphosphonate in der Onkologie (2003) (2)
A renal cancer cell (RENCA) vaccine successfully inhibits tumor induction and progression in a murine renal cancer model. (2004) (2)
Pilot study on outcome and antitumor efficacy of an autologous cancer cell vaccine applied in patients with advanced solid tumors. (2020) (1)
135 A clinical phase I dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of BIBF 1120 in advanced cancer patients (2004) (1)
Glutaminase (PEG-PGA) increases antitumoral efficacy of cytotoxic agents. (2004) (1)
Cediranib targeting of circulating VEGFR-1+ monocyte subpopulations (2008) (1)
Effects of adriamycin and interferon, applied in metronomic doses, on tumor volume, metastases and vessel density in murine renal cell carcinoma (2001) (1)
[Receptor tyrosine kinases. A target for new cancer treatments]. (2004) (0)
Anti-tumor effects of AMT in the renal cell carcinoma model. (2009) (0)
Increased angiogenesis in bone metastases of patients with metastatic breast cancer (2001) (0)
Vascular Biomarkers and Imaging Studies (2012) (0)
Contents of Next Issues · Themenvorschau (2002) (0)
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. (2013) (0)
Complete Contents Vol. 25, 2002 (2002) (0)
Efficient autologous inhibition of tumor growth in a murine model of renal carcinoma (1999) (0)
Biomarkers in Tumor Angiogeneis and Anti-Angiogenic Therapy (2011) (0)
Glutaminase (PEG-PGA) increases antitumoral efficacy of cytotoxic agents (2004) (0)
Kidney Cancer Mode-of-Action , Efficacy , and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma (2009) (0)
List of Referees, 2009 (2010) (0)
Band 25, Heft 6, December 2002 (2002) (0)
Complete Contents Vol. 2, 2001 (2001) (0)
Phase II/III study of Auron Misheil Therapy (AMT) versus placebo to evaluate clinical benefit response (CBR) in patients with advanced solid tumors. (2009) (0)
UICC Symposium on Testicular Cancer Tübingen 19./20. März 1999 (1999) (0)
Band 22, Heft 4, August 1999 (1999) (0)
Clinical Development of the VEGFR Signalling Inhibitor AZD2171 (2008) (0)
Pilot study on antitumor efficacy of intravenously applied synergistic combinations of salicylic acids in patients with advanced solid tumors. (2012) (0)
[Bisphosphonates in oncology]. (2003) (0)
1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours (2009) (0)
A RENAL CANCER (RENCA) VACCINE INHIBITS TUMOUR GROWTH IN THE MURINE RENCA MODEL (2006) (0)
Additive/synergistic efficacy of zoledronic acid and LBH589 in the spheroid-based cellular angiogenesis assay. (2009) (0)
Abstracts – Fatigue and Cancer. International Symposium, Köln, 03.–04.09.1999 (1999) (0)
Subject Index Vol. 25, 2002 (2002) (0)

This paper list is powered by the following services:

Other Resources About Joachim Drevs

en.wikipedia.org

What Schools Are Affiliated With Joachim Drevs?

Joachim Drevs is affiliated with the following schools: